BACKGROUND: To date, the etiology of primary tumors of the central nervous system (mainly gliomas and meningiomas) is poorly understood. The role of sex hormones has been suggested, based on clinical, experimental, biological, and epidemiological data. OBJECTIVE: To review the epidemiological studies on the relation between hormonal factors and the occurrence of glioma and meningioma, in order to identify new research developments. METHODS: Articles published until September 2010 were selected by considering exogenous and endogenous exposures and specific brain tumors. Standardized information was collected from 20 articles: 15 concerning gliomas and 13 meningiomas. RESULTS: An increased glioma risk was observed with later menarche and menopause, while a reduced glioma risk was observed with hormone replacement therapy (HRT) and oral contraceptive use, despite duration of use had no effect on risk. Meningioma risk increased after menopause and with HRT use. No clear association was found with pregnancy and breastfeeding. CONCLUSION: Results are globally concordant with the biologic hypothesis assuming that female sex hormones are protective against glioma and may increase the risk of meningioma. However, new epidemiological studies should be conducted in order to confirm these associations and to refine the role of hormonal factors in brain etiology.
BACKGROUND: To date, the etiology of primary tumors of the central nervous system (mainly gliomas and meningiomas) is poorly understood. The role of sex hormones has been suggested, based on clinical, experimental, biological, and epidemiological data. OBJECTIVE: To review the epidemiological studies on the relation between hormonal factors and the occurrence of glioma and meningioma, in order to identify new research developments. METHODS: Articles published until September 2010 were selected by considering exogenous and endogenous exposures and specific brain tumors. Standardized information was collected from 20 articles: 15 concerning gliomas and 13 meningiomas. RESULTS: An increased glioma risk was observed with later menarche and menopause, while a reduced glioma risk was observed with hormone replacement therapy (HRT) and oral contraceptive use, despite duration of use had no effect on risk. Meningioma risk increased after menopause and with HRT use. No clear association was found with pregnancy and breastfeeding. CONCLUSION: Results are globally concordant with the biologic hypothesis assuming that female sex hormones are protective against glioma and may increase the risk of meningioma. However, new epidemiological studies should be conducted in order to confirm these associations and to refine the role of hormonal factors in brain etiology.
Authors: Quinn T Ostrom; Maral Adel Fahmideh; David J Cote; Ivo S Muskens; Jeremy M Schraw; Michael E Scheurer; Melissa L Bondy Journal: Neuro Oncol Date: 2019-11-04 Impact factor: 12.300
Authors: Anna R Terry; Fred G Barker; Lisa Leffert; Brian T Bateman; Irene Souter; Scott R Plotkin Journal: Neuro Oncol Date: 2012-04-18 Impact factor: 12.300
Authors: Siegal Sadetzki; Angela Chetrit; Michelle C Turner; Martie van Tongeren; Geza Benke; Jordi Figuerola; Sarah Fleming; Martine Hours; Laurel Kincl; Daniel Krewski; Dave McLean; Marie-Elise Parent; Lesley Richardson; Brigitte Schlehofer; Klaus Schlaefer; Maria Blettner; Joachim Schüz; Jack Siemiatycki; Elisabeth Cardis Journal: J Neurooncol Date: 2016-09-23 Impact factor: 4.130
Authors: Joseph L Wiemels; Paige M Bracci; Margaret Wrensch; Joellen Schildkraut; Melissa Bondy; Jon Pfefferle; Mi Zhou; Jennette Sison; Lisa Calvocoressi; Elizabeth B Claus Journal: Am J Epidemiol Date: 2012-12-06 Impact factor: 4.897
Authors: Elizabeth B Claus; Lisa Calvocoressi; Melissa L Bondy; Margaret Wrensch; Joseph L Wiemels; Joellen M Schildkraut Journal: J Neurosurg Date: 2012-10-26 Impact factor: 5.115
Authors: Gabriella M Anic; Melissa H Madden; L Burton Nabors; Jeffrey J Olson; Renato V LaRocca; Zachary J Thompson; Shitaldas J Pamnani; Peter A Forsyth; Reid C Thompson; Kathleen M Egan Journal: J Neurooncol Date: 2014-04-04 Impact factor: 4.130